Abstract
Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease reflecting an imbalance between regulatory and effector immune responses. With the rapid development of molecular biology and multi-omics, the pathogenesis of SLE has been gradually elucidated. In particular, imbalances and abnormalities in immune cell function have been shown to play an important role in the development of SLE. Understanding the specific pathogenesis of SLE is the basis for targeted therapy against specific targets. In this review, we describe the latest research progress on the involvement of immune cells in the pathogenesis of SLE and the potential of targeting different immune cells for therapeutic purposes. Then the importance of precision medicine for SLE disease management is also discussed. Finally, we emphasize recent advances in nanoparticle (NPs)-mediated drug delivery systems for targeted therapy of SLE.
Keywords
Systemic lupus erythematosus, Pathogenesis, Immune cells, Target therapy, Nanoparticles